

IMMUNOTHERAPY OF CANCER

Dr Fatima Khatoon^{1*}, Fatima Jabeen¹, Dr Syed Mohammed Kazim², Dr M A Aleem², Dr Nabeela Fatima²

¹Department of Pharmacy, Nizam Institute of Pharmacy, Deshmukhi, Telangana, India-508284

²Department of pharmacy, Nizam Institute of Pharmacy, Deshmukhi, Telangana, India-508284

Corresponding Author:

Dr Fatima Khatoon

Department of Pharmacy Practice,

Nizam Institute of Pharmacy, Deshmukhi.

Email: fak89867@gmail.com

Phone: +91-9505547994

ABSTRACT: cancer immunotherapy is an approach to treating malignancies nowadays.

Immunotherapy has been shown in numerous assessments and clinical research to offer unrivaled blessings over traditional anti-tumor remedies, which could increase progression-unfastened survival (PFS) and normal survival (OS). Immunotherapy is difficult and unreliable. because of an overactive immune device, immunotherapy may additionally occasionally result in critical terrible facet effects. Immunological checkpoints that are greatly green and motivate fewer aspect outcomes are presently being researched. By way of weighing the blessings and drawbacks of immunotherapy and keeping a close eye on immunotherapy's destiny improvement trend, this take look gives a top-level view of present-day advances in immunotherapy and indicates a new technique for treating tumours.

key phrases: cancer immunotherapy; Immune checkpoint inhibitors; Tumor microenvironment; car-T; PD-1

1. INTRODUCTION:

Immunotherapy is a cancer remedy that, in comparison to traditional cancer therapies like radiotherapy and chemotherapy, dynamically modifies the immune gadget to assault most

cancers cells in a spread of goals and orientations. [1]. Immunotherapy is primarily used to boost vulnerable function by controlling the immunological medium, which enables vulnerable cells to target and annihilate tumour cells at several significant bumps [2]. utmost of the goods will be vastly bettered when used in combination with conventional anti-tumour remedies or multitudinous vulnerable checkpoint impediments(ICIs), although further exploration is demanded to determine the exact circumstances. The market and use of pharmaceuticals are gradually expanding, and associated anti-tumour medication research is becoming more in-depth. At present, the gap with the transnational exploration position is gradationally narrowing, which greatly promotes the development of tumour immunotherapy




Fig-1: Cancer Immunotherapy [Adapted from Ashu Tripathi et al]

2. CELLULAR IMMUNOTHERAPY FOR TUMOURS: Immune cells can identify and kill tumours. By stimulating vulnerable cells and using the body's tumour-specific vulnerable response to overcome tumour escape, vulnerable cells can formerly again play a part in tumour surveillance and concurrence. Cell immunotherapy is now effective in hematologic tumours, but due to the diversity within solid tumours and external microenvironments, the efficacy for solid tumours is not as anticipated. (3).

i) **Adaptive cellular immunotherapy [ACI]:**

The process of destroying tumor cells by injecting genetically modified immunological effector cells that has amplified and become a popular research field and important treatment method due to its high specificity, easy preservation, and absence of drug resistance is known as ACI. ACI can be categorized into nonspecific and specific ACI. In nonspecific ACI, immune cells are activated by cytokines or lymphocytes present in the peripheral blood and can be used to treat a variety of tumors. However, their weak killing ability and poor targeting restrict them to adjuvant therapy. Dendritic cells(DC), natural killer cells(NKC), cytokine-convincing killer cells(CIK), exscrencence- insinuating lymphocytes (TIL), lymphocyte-actuated killer cells(LAK), macrophages-actuated killer cells(MAK), and so on are the immunologic effector cells in nonspecific ACI. Specific ACI involves the induction of immune cells by specific tumor antigen stimulation and stimulating factors like TIL therapy, T cell receptor -T (TCR-T), and Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T). [4] The principal effector cells are CD8 + T cells and CD4 + T Cells. This kind of therapy has strong specificity, a strong focus on, excessive lethality, small side outcomes, and o drug resistance, so it can be used in a few advanced patients or patients and not using a reaction to other healing outcomes. TIL therapy is most effectively used for cancer quickly due to its difficulty in isolating and accumulating, and car-T remedy is frequently used for blood tumour remedy. [5]




FIG-2: Adaptive cellular immunotherapy [Adapted from Qiaofei Liu]

ii) **NK Cell therapy:** The floor of NK cells, which might be risky herbal immune cells, is often made from lively killer activation receptors (KARs) and killer inhibitory receptors (KIRs). while NK cells may also hastily respond to viral infection and tumor incidence, they're aware that everyday cells are often controlled by means of inhibitory receptors and keep away from killing them. To destroy the immune system and release a wellknown immune device defense and assault, NK cells do now not even need to be activated in the absence of an antibody. especially for metastatic cancers and blood tumors, the deadly impact of NK cells on tumor cells missing the MHC-1 receptor and tumor cells expressing the activated ligand with up-regulated expression was activated. [6] additionally, energetic cytokines like IL-2 and IL-5 mediate and encourage NK mobile activation, even as antibody-established cellular-mediated cytotoxicity (ADCC) facilitates NK cells' capability to locate and eradicate tumor cells which have been coated with an antibody. Newly created BiKE and TriKE molecules may boost ADCC's efficiency. [7] To circumvent the immune system, tumor cells still possess the mechanisms that suppress NK cells. [8] First, MICA and MICB proteins are secreted by tumor cells. Accordingly, specific antibodies have been designed and have produced outcomes, such as mAb 7C6. [9] second, through increasing the expression of HLA-G and interacting with the NK cells' inhibitory receptor LIR-1, tumor cells prevent NKC from being detected and killed. Thirdly, the soluble activated NKG2D ligand is secreted and dispersed by using tumor cells, making it extra tough for NK cells to hook up with the NKG2D ligand on tumors and allowing for persistent activation of NK cells near the tumor, which lowers the sensitivity of popularity. [10] Inhibitory immune cells can hinder NK cells' anti-tumor activity through cytokine secretion or direct contact. [11] NK cell treatment can be improved by blocking inhibitory signaling pathways, activating activation signaling pathways, or using targeted drugs to promote NK cells' migration to the tumor site, thus enhancing anti-tumor effects and minimizing side effects. [12] Medical research focuses on NK cells with immune checkpoint inhibitors, CAR-combined NK cells, and NK cell-based immunotherapy. [13]




Fig-3: NK cell activation and suppression.

Figure 3 displays the techniques used to activate and inhibit NK cells. KAR and KIR are components of NK cells. The signals that activate and suppress NK cells control how they react to tumor cells. Decreased MHC-1 molecule binding to inhibitory receptor KIR is one of the

causes of NK cell activation. They were increasing the amount of binding to active antigens. ICIs were used to eliminate immunosuppression signals. ADCC acts as a mediator in the detection and elimination of tumor cells. Cytokines encourage NK cell activation. Tumor cells upregulate the expression of the HLA-G molecule can be increased to enhance its binding affinity with the inhibitory LIR-1 receptor, which is one of the methods by which NK cells are inhibited. The activity of the antibodies is downregulated as a result of the connection of the interaction between the tumor cell expressing NKG2DL and the NK cell expressing NKG2D.).

iii) CAR-t immunotherapy:

Certain B cell malignancies can be treated with this particular treatment, therapies using genetically altered T cells that express CARs that are specific for CD19 or BCMA are licensed. The threat of clinically extreme on-goal, off-tumour toxicity (OTOT) because of automobile T cellular-mediated cytotoxicity in opposition to non-malignant tissues expressing the target antigen is one of the difficulties in turning these achievements into therapies for patients with solid tumours. certainly, severe OTOT has been cited in numerous car T cellular clinical studies which include patients with stable tumours, underscoring the need to increase techniques to anticipate, reduce, and manage the development of this effect. This review discusses recent clinical data supporting the use of CAR T cells for solid tumors. We examine the usefulness of preclinical mice models in predicting clinical outcomes. New approaches to improve the specificity of CAR T cells in treating solid tumors are highlighted. Control methods to reduce clinical OTOT after cell infusion are also emphasized. [14]

CAR architecture is shown below. Standard CAR has an intracellular CD3 signaling domain, scFv produced from a monoclonal antibody, connected via TM to a co-stimulatory signaling domain (e.g., CD28 or 4-1BB). While CD28 provides for quick growth but limited endurance, 4-1BB encourages persistent effector function. Immunoreceptor Tyrosine-primarily based Activation Motif, Immunoreceptor Heavy Chain Variable area, Immunoreceptor light Chain Variable area.




Fig-4: The CAR-t architecture

3. FACTOR INFLUENCING TUMOR IMMUNOTHERAPY:

- a) **EFFECT ON EFFICIENCY:** Numerous factors affect how tumour immunotherapy works. First, it has to do with human immunity, which has strong genetic and internal microbial ties. [15] It has to do with malignant cells, second. Patients with low intra-tumor heterogeneity and high clonal source neoantigens have greater therapeutic benefits. [16] Other significant factors affecting the therapeutic effect include a number of new antigens, tumour mutation targets, and mutation load. Thirdly, environmental variables including daily routine, food, bacterial illness, and drug usage are connected to it.

- b) EFFECT ON INTESTINAL BACTERIA:** Based on their immunological features, There are three types of tumors. The first type is "immunosuppressed" or "immune desert type". This type lacks T cells or has a low density of lymphocytes. PD-1/PD-L1 treatments are generally ineffective for this type of tumor.. The second kind, also known as the "immune excluded" or "Immune exemption type" tumours exhibit high concentrations of CD3+ and CD8+ lymphocytes at the tumour's periphery. However, the center of the tumour cannot be engulfed by these cells. T-cell emigration is the primary cause of immune response suppression. The third kind is called the immunological inflammatory type, and it surrounds the tumour with PD-L1, pro-inflammatory factors, and effectors, but an immune response is blocked by the tumour's escape. [17] To treat certain types of cancers, methods like T-cell transport regulators, soluble factor regulators, and physical barrier-destroying techniques can be used. [18]
- c) NEOANTIGENS:** Anti-PD1/CTLA4 immunotherapy is less effective due to intratumoral heterogeneity of neoantigens, insufficient clonal neoantigens, and a surge in subclonal neoantigens.[19] The more clone-derived novel antigens present and the less heterogeneity there is in the tumor, the longer the total survival period. Clonogenic neoantigens may be correlated with effector T cell activation in the tumor environment. This is evident by the higher number of clonal neoantigens and higher expression of pro-inflammatory genes such as PD-L1, IL-6, and IFN in tumors.. [20]
- d) EFFECT OF TUMOR MICROENVIRONMENT:** the tumor cells, peripheral immune cells, neovascularization, fibroblasts, endothelial cells, and extracellular matrix. In clinical practice, the type, quantity, and other properties of immune cells present in the tumor core and its surrounding microenvironment have a significant impact. may be used to approximately predict the degree of tumour degeneration, probability, and impact of immunotherapy medicines. In the meantime, immunotherapy for inflammatory tumors is influenced by both genetic and environmental factors. Critical proteins, inflammatory mediators, and inflammatory cells are all potential drug targets for inflammatory signaling

pathways. [22] Even if the efficacy is still unpredictable, it lays the foundation for improvement and enables patients to get tailored therapy.

Most cancer cells respond well to PD-1/PD-L1 inhibitors, especially those with high PD-1 expression, high mutation loads, and specific indicators like IFN-, granzyme, and CXCL9/CXCL10. MDSCs and macrophages can also contribute to tumor growth by depleting extracellular arginine and promoting tryptophan breakdown., are immunosuppressive drivers in the tumour microenvironment, where Cancer-associated fibroblasts (CAFs) cause the death of T cells by attaching to them.. [23] Additionally, the tumour microenvironment's acidic and hypoxic circumstances promote tumour growth and reproduction, prevent T cells from activating and becoming toxic, and severely suppress the tumour's ability to evade the immune system's defenses.[24]

- e) **Tumor Mutational Burden (TMB)** plays a crucial role in tumor immunotherapy. As the tumor mutation loads rise, more novel antigens are produced, which activate T cell responses. This makes immunotherapy more effective as its effects become more visible. Further research has indicated that the number of mutations or mutation load in a tumor's DNA can be used as immunological markers to predict the impact of immunotherapy. This helps in directing clinical trials, including immunotherapy. Additionally, following therapy, TMB has been shown to extend progression-free survival (PFS) and overall survival (OS). [25,26]

4. IMMUNE CHECKPOINT INHIBITORS:

Immune checkpoints are networks of pathways that regulate immune response and self-tolerance. Activated in cancer to suppress antitumor immune response. Immune checkpoint drugs increase the body's ability to fight malignant tumours by inhibiting or enhancing these pathways. These three inhibitory checkpoint pathways – CTLA-4, PD-1, and PD-L1 are molecules involved in cell death regulation. have received the greatest attention. For research. Drugs that disrupt these pathways are now used for the treatment of various types of cancers. and have been shown to have long-lasting therapeutic effects in some cancer patients. New research in cancer treatments has shown that inhibitory mechanisms such as CTLA-four and PD-1/PD-L1 are no longer sufficient. Instead, scientists are exploring the potential benefits of pills that block other inhibitory

mechanisms such as LAG-three, TIM-3, TIGIT, VISTA, and B7/H3. Furthermore, agonists of the stimulation checkpoint pathway such as OX40, ICOS, GITR, 4-1BB, and CD40 are also being investigated., as well as compounds targeting elements of the tumor microenvironment such as IDO or TLRs, are also being researched. Immune control pathways involved in cancer immunotherapy have been reviewed in depth in this article, along with protocols and treatments that have been tested In phase I clinical trials, we discuss disadvantages, side effects, difficulties, and future research possibilities. [27]




Fig-5: Interactions between the tumor microenvironment, T cells interact with antigen-presenting cells and tumor cells.

5. DRUGS USED IN CANCER IMMUNOTHERAPY:

5.1 PEMBROLIZUMAB:

BRAND NAME: Keytruda.

DOSES: 100mg/4mL (25mg/mL)

USES:

- Solid Tumors

- Malignant Melanoma.
- Head and neck cancer.
- Non-Small Cellular Lung Cancer
- Lymphoma.

ADVERSE EFFECT: Unresectable or metastatic melanoma: rash, constipation, fatigue, arthralgia, cough, decreased appetite, pyrexia, abdominal pain, asthenia, , hyperglycemia, hypertriglyceridemia, hypoalbuminemia, lymphopenia, , hypercholesterolemia.

CONTRAINDICATION: There are not any contraindications for pembrolizumab. boundaries of use: Pembrolizumab isn't endorsed in PMBCL (primary mediastinal big B-mobile lymphoma) sufferers who require urgent cytoreductive remedy.

5.2 NIVOLUMAB:

BRAND NAME: OPDIVO

DOSES: Applies to the following strengths: 10 mg/mL

USES:

- skin cancer (melanoma).
- non-small cell lung cancer.
- Renal cell cancer.
- Liver cancer, or
- Colorectal cancer.

ADVERSE EFFECT: signs and symptoms of a hypersensitive reaction to Opdivo (hives, hard breathing, swelling to your face or throat) or a severe pores and skin response (fever, sore throat, burning eyes, skin pain, pink or red pores and skin rash with blistering and peeling).

CONTRAINDICATION: Hypersensitivity to nivolumab or any components of the formulation.

5.3 CEMIPILIMAB:

BRAND NAME: Libtayo.

DOSES: Applies to the following strengths: rwlc 350 mg/7 mL

USES:

- Non-small cell lung cancer
- Cutaneous squamous cell carcinomas [cscC ; skin cancer].
- Basal cell carcinoma (BCC).

ADVERSE EFFECT: Diarrhoea, painful or difficult urination, fever, hoarseness, itching, skin rash.

CONTRAINDICATION: This drug is not recommended for use in children

5.4 TORIPALIMB:

BRAND NAME: Loqtorzi

DOSES: 240 mg Q3W, tolerated up to 10 mg/kg Q2W

USES:

- Melanoma
- Nasopharyngeal carcinoma
- Urothelial carcinomas.
- neuroendocrine neoplasms.
- lung cancer.

ADVERSE EFFECT: Pneumonitis, may cause new trouble breathing, cough, or chest pain.

CONTRAINDICATION: None

5.5 SINTILIMAB:

BRAND NAME: Tyvyt

DOSES: 10 mg/kg. sooner or later, a dose of 200 mg in line with three weeks (q3w)

USES:

- it is used for the treatment of relapsed or refractory classical Hodgkin's lymphoma after failure of at least 2d-line systemic chemotherapy.

ADVERSE EFFECT: Fever, thyroid dysfunction, elevation of liver enzymes, and lung irritation.

CONTRAINDICATION: None

5.6 PIDILIZUMAB:

BRAND NAME: CT-011; MDV 9300

DOSES: 3 mg/kg intravenously each 4 weeks for four infusions.

USES:

- It is used for treatment of cancer and infectious disease

ADVERSE EFFECT: Colitis, diarrhoea, malignancies.

CONTRAINDICATION: None

5.7 ATEZOLIZUMAB:

BRAND NAME: Tecentriq

DOSES: 840 mg IV q2Weeks or; 1200 mg IV q3Weeks.

USES:

- It is used alone to help prevent non-small cell lung cancer (NSCLC)

ADVERSE EFFECT: Pale skin, loss of appetite, vomiting, constipation, hair loss.

CONTRAINDICATION: May cause foetal harm if used during pregnancy.

5.8 DURVALUMAB:

BRAND NAME: Imfinzi

DOSES: 120 mg/2.4mL (50mg/mL),

500 mg/10mL (50mg/mL).

USES:

- It is used to treat non-small cell lung cancer (NSCLC).

ADVERSE EFFECT: Fatigue, Infusion-related reactions, Musculoskeletal pain, Swelling of extremities, Urinary tract infection (UTI),

CONTRAINDICATION: None.

5.9 AVELUMAB:

BRAND NAME: BAVENCIO

DOSES: 800 mg IV q2Weeks. Continue until disease progression.

USES:

- it's miles used to deal with Merkel cell carcinoma (MCC; a form of skin cancer)

ADVERSE EFFECT: Fatigue, headache, musculoskeletal pain, arthralgia, abdominal pain

CONTRAINDICATION: Hypersensitivity to the active substance or to any of the excipients.

5.10 IPILIMUMAB:

BRAND NAME: YERVOY

DOSES: Single agent. ≥ 12 years: three mg/kg IV q3Weeks for a maximum of 4 doses.

USES:

- It is used in the management and treatment of metastatic melanoma.

ADVERSE EFFECT: Fatigue, diarrhea, pruritus, rash, and colitis.

CONTRAINDICATION: Hypersensitivity to ipilimumab or any component of the formulation.

5.11 TRASTUZUMAB:

BRAND NAME: Herxuma, Kanjinti or Ontruzant

DOSES: [weekly agenda: 2 mg/kg; three-weekly timetable: 6 mg/kg].

uses:

- Breast cancers
- advanced stomach cancer
- most cancers wherein the food pipe joins your stomach (gastro-oesophageal junction).

ADVERSE EFFECT: Headache. Gastrointestinal signs (nausea and vomiting; belly pain, diarrhea), back pain, top breathing signs (rhinitis, pharyngitis), weak spots, and fatigue.

CONTRAINDICATION: hypersensitivity to trastuzumab treatment or murine proteins, severe dyspnea at rest as a consequence of complications of superior malignancy, and requiring supplementary oxygen remedy

15.12 BEVACIZUMAB:

BRAND NAME: Avastin

DOSES: prOC · Topotecan (each 3 weeks), 15 mg/kg IV, every 3 weeks; rGBM · none (single agent), 10 mg/kg IV, each 2 weeks.

uses:

- To treat positive sorts of colon and rectal cancer (most cancers that start in the large gut)
- Non-small cellular lung cancer (NSCLC)
- Glioblastoma (a positive form of cancerous mind tumor)
- Renal cellular cancer (RCC, a type of most cancers)

ADVERSE EFFECT: mild-headed, itchy, sweaty, or have a headache, chest tightness, returned ache, trouble breathing, or swelling in your face.

CONTRAINDICATION: which includes pulmonary embolism, stroke, coronary heart assault, deep vein thrombosis

5.13. PANITUMUMAB:

BRAND NAME: Vectibix

DOSES: usually every 14 days. The dosage is primarily based on your weight and response to treatment

USES:

- it's miles used to deal with a type of cancer of the colon or rectum that has unfolded to other regions of the body both at some point of or after treatment with other chemotherapy capsules.

ADVERSE EFFECT: respiratory problems, modifications in imagination and prescient, eye pain, fast irregular heartbeat, fever, and chills.

CONTRAINDICATION: This does not work in patients who have KRAS or NRAS mutations.

5.14 RITUXIMAB:

BRAND NAME: Rituxan

DOSES: injectable answer (single-dose vials), 10mg/mL (10mL, 50mL vials)

USES:

- it's miles used to deal with certain forms of cancer like non-Hodgkin lymphoma and continual lymphocytic leukemia.

ADVERSE EFFECT: Fever, chills or shaking, dizziness, problem breathing, itching or rash, lightheadedness or fainting.

CONTRAINDICATION: extreme, active contamination, hypersensitive reaction to any of the components of the formulation. intense heart failure, uncontrolled cardiac disease, being pregnant.

5.15ALDESLEUKIN:

BRAND NAME: Proleukin

DOSES: The advocated dose is 600,000 IU/kg intravenously over 15 minutes each eight hours for 14 doses accompanied by means of nine days of relaxation.

USES:

- it's miles used to deal with superior renal cellular carcinoma (RCC, a kind of cancer that starts inside the kidney) that has unfolded to different elements of your body.
- extensively utilized to deal with melanoma (a form of skin most cancers) that has spread to other parts of your body.

ADVERSE EFFECT: Apillary leak syndrome (a circumstance that causes the body to keep extra fluid, low blood stress, and coffee stages of a protein [albumin] within the blood) which may additionally result in harm to your coronary heart, lungs, kidneys, and gastrointestinal tract.

CONTRAINDICATION: patients with a regarded history of hypersensitivity to interleukin-2 or any aspect of the Proleukin method.

CONCLUSION:

These days, the significance of anti-tumor immunotherapy inside the subject of tumor remedy is developing. Studies on the treatment of a range of malignant tumors have produced encouraging results, and new approaches and targets, such as combination therapy, have increased the efficacy of immunotherapy and lowered its negative effects. The unpredictability of therapeutic outcomes, high expense of care, rare cases of severe adverse reactions, sometimes even life-threatening ones, and treatments that could result in blindness are all reasons why immunotherapy is still debatable today.

REFERENCES:

1. Couzin-Frankel J. Cancer immunotherapy.
2. Chevolet IN, Speeckaert R, Schreuer M, Neyns B, Krysko O, Bachert C, Hennart B, Allorge D, van Geel N, Van Gele M, Brochez L. Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma. *Oncoimmunology*. 2015 Mar 4;4(3):e982382.
3. Ikeda H, Shiku H. Immunotherapy of solid tumor: perspectives on vaccine and cell therapy. *Nihon rinsho. Japanese Journal of Clinical Medicine*. 2012 Dec 1;70(12):2043-50.

4. Marei HE, Althani A, Caceci T, Arriga R, Sconocchia T, Ottaviani A, Lanzilli G, Roselli M, Caratelli S, Cenciarelli C, Sconocchia G. Recent perspective on CAR and Fcγ-CR T cell immunotherapy for cancers: Preclinical evidence versus clinical outcomes. *Biochemical Pharmacology*. 2019 Aug 1;166:335-46.
5. Panda A, Betigeri A, Subramanian K, Ross JS, Pavlick DC, Ali S, Markowski P, Silk A, Kaufman HL, Lattime E, Mehnert JM. Identifying a clinically applicable mutational burden threshold as a potential biomarker of response to immune checkpoint therapy in solid tumors. *JCO precision oncology*. 2017 Dec;1:1-3.
6. Shevtsov M, Multhoff G. Immunological and translational aspects of NK cell-based antitumor immunotherapies. *Frontiers in immunology*. 2016 Nov 11;7:492.
7. Davis ZB, Vallera DA, Miller JS, Felices M. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy. In *Seminars in immunology 2017 Jun 1 (Vol. 31, pp. 64-75)*. Academic Press.
8. Cantoni C, Huergo-Zapico L, Parodi M, Pedrazzi M, Mingari MC, Moretta A, Sparatore B, Gonzalez S, Olive D, Bottino C, Castriconi R. NK cells, tumor cell transition, and tumor progression in solid malignancies: new hints for NK-based immunotherapy?. *Journal of immunology research*. 2016 Oct;2016.
9. Ferrari de Andrade L, Tay RE, Pan D, Luoma AM, Ito Y, Badrinath S, Tsoucas D, Franz B, May Jr KF, Harvey CJ, Kobold S. Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity. *Science*. 2018 Mar 30;359(6383):1537-42.
10. H. Saito, T. Osaki, M. Ikeguchi. Decreased NKG2D expression on NK cells correlates with impaired NK cell function in patients with gastric cancer. *Gastric Cancer*, pp. 27-33
11. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. *Nature*. 2011 Dec 22;480(7378):480-9.
12. Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. *Nature Reviews Cancer*. 2016 Jan;16(1):7-19.
13. Siegler EL, Zhu Y, Wang P, Yang L. Off-the-shelf CAR-NK cells for cancer immunotherapy. *Cell stem cell*. 2018 Aug 2;23(2):160-1.

14. Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, Wagner DL, Abou-el-Enein M. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. *Nature Reviews Clinical Oncology*. 2023 Jan;20(1):49-62.
15. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Man Lei Y, Jabri B, Alegre ML, Chang EB. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. *Science*. 2015 Nov 27;350(6264):1084-9.
16. McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birnbak NJ, Hiley CT, Watkins TB. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. *Science*. 2016 Mar 25;351(6280):1463-9.
17. Riegger T, Conrad S, Schluesener HJ, Kaps HP, Badke A, Baron C, Gerstein J, Dietz K, Abdizahdeh M, Schwab JM. Immune depression syndrome following human spinal cord injury (SCI): a pilot study. *Neuroscience*. 2009 Feb 6;158(3):1194-9.
18. Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. *Nature reviews Drug discovery*. 2019 Mar;18(3):197-218.
19. Linette GP, Becker-Hapak M, Skidmore ZL, Baroja ML, Xu C, Hundal J, Spencer DH, Fu W, Cummins C, Robnett M, Kaabinejadian S. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens. *Proceedings of the National Academy of Sciences*. 2019 Nov 19;116(47):23662-70.
20. Liu J, Li D, Luo H, Zhu X. Circular RNAs: the star molecules in cancer. *Molecular aspects of medicine*. 2019 Dec 1;70:141-52.
21. Zhu X, Luo H, Xu Y. Transcriptome analysis reveals an important candidate gene involved in both nodal metastasis and prognosis in lung adenocarcinoma. *Cell & Bioscience*. 2019 Dec;9:1-3.
22. Zhu X, Lin MC, Fan W, Tian L, Wang J, Ng SS, Wang M, Kung H, Li D. An intronic polymorphism in GRP78 improves chemotherapeutic prediction in non-small cell lung cancer. *Chest*. 2012 Jun 1;141(6):1466-72.
23. Kim S, Nam SJ, Park C, Kwon D, Yim J, Song SG, Ock CY, Kim YA, Park SH, Kim TM, Jeon YK. High tumoral PD-L1 expression and low PD-1+ or CD8+ tumor-infiltrating

lymphocytes are predictive of a poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system. *Oncoimmunology*. 2019 Sep 2;8(9):e1626653.

24. Sun Y, Wang R, Qiao M, Xu Y, Guan W, Wang L. Cancer associated fibroblasts tailored tumor microenvironment of therapy resistance in gastrointestinal cancers. *Journal of cellular physiology*. 2018 Sep;233(9):6359-69.
25. Jensen C, Madsen DH, Hansen M, Schmidt H, Svane IM, Karsdal MA, Willumsen N. Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients. *Journal for Immunotherapy of Cancer*. 2018 Dec;6(1):1-0.
26. Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. *New England Journal of Medicine*. 2017 Dec 21;377(25):2500-1.
27. Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S, Lou Y. Next generation of immune checkpoint therapy in cancer: new developments and challenges. *Journal of hematology & oncology*. 2018 Dec;11:1-20.

-----..THE END..-----
